These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 23712328)

  • 1. A phase I trial of oxaliplatin in combination with docetaxel in patients with advanced solid tumors.
    Iqbal S; Lenz HJ; Gandara DR; Shibata SI; Groshen S; Synold TW; Newman EM
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):85-91. PubMed ID: 23712328
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I study of intravenous (IV) docetaxel and intraperitoneal (IP) oxaliplatin in recurrent ovarian and fallopian tube cancer.
    Taylor SE; Li R; Petschauer JS; Donovan H; O'Neal S; Keeler AW; Zamboni WC; Edwards RP; Zorn KK
    Gynecol Oncol; 2015 Sep; 138(3):548-53. PubMed ID: 26111788
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A dose-escalation study of pemetrexed and docetaxel in non-small-cell lung cancer.
    Kotsakis A; Agelaki S; Vardakis N; Stathopoulos G; Vamvakas L; Kalykaki A; Kentepozidis N; Kontopodis E; Sfakiotaki G; Mavroudis D; Georgoulias V
    Cancer Chemother Pharmacol; 2011 Aug; 68(2):415-22. PubMed ID: 21069335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I study of 3-weekly docetaxel, capecitabine and oxaliplatin combination chemotherapy in patients with previously untreated advanced gastric cancer.
    Sym SJ; Ryu MH; Kang HJ; Lee SS; Chang HM; Lee JL; Kim TW; Yook JH; Oh ST; Kim BS; Kang YK
    Cancer Chemother Pharmacol; 2010 Jul; 66(2):373-80. PubMed ID: 19936751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase 1a/1b and pharmacogenetic study of docetaxel, oxaliplatin and capecitabine in patients with advanced cancer of the stomach or the gastroesophageal junction.
    Deenen MJ; Meulendijks D; Boot H; Legdeur MC; Beijnen JH; Schellens JH; Cats A
    Cancer Chemother Pharmacol; 2015 Dec; 76(6):1285-95. PubMed ID: 26499900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A dose escalation study of docetaxel plus capecitabine in combination with oxaliplatin in patients with advanced solid tumors.
    Amarantidis K; Xenidis N; Chelis L; Chiotis A; Tentes A; Chatzaki E; Kortsaris A; Polychronidis A; Karakitsos P; Kakolyris S
    Acta Oncol; 2010; 49(2):245-51. PubMed ID: 19839918
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A dose-escalation and pharmacokinetic study of gemcitabine and oxaliplatin in patients with advanced solid tumors.
    Mavroudis D; Pappas P; Kouroussis C; Kakolyris S; Agelaki S; Kalbakis K; Androulakis N; Souglakos J; Vardakis N; Nikolaidou M; Samonis G; Marselos M; Georgoulias V
    Ann Oncol; 2003 Feb; 14(2):304-12. PubMed ID: 12562660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Phase I study of the combination of oxaliplatin/docetaxel and vandetanib for the treatment of advanced gastroesophageal cancer.
    Halmos B; Jia Y; Bokar JA; Fu P; Adelstein DJ; Juergens R; Rodal MB; Dowlati A
    Invest New Drugs; 2013 Oct; 31(5):1244-50. PubMed ID: 23553066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I clinical and pharmacokinetic/pharmacogenetic study of a triplet regimen of S-1/irinotecan/oxaliplatin in patients with metastatic colorectal or gastric cancer.
    Park SR; Hong YS; Lim HS; Seong MW; Kong SY; Kim SY; Park YI; Jung KH
    Cancer Chemother Pharmacol; 2013 Nov; 72(5):953-64. PubMed ID: 23982118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A multicenter phase II study of docetaxel, oxaliplatin, and bevacizumab in first-line therapy for unresectable locally advanced or metastatic non-squamous cell histology non-small-cell lung cancer (NSCLC).
    Raez LE; Santos ES; Webb RT; Wade J; Brito RA; Karr M; Kennah A; Childs BH
    Cancer Chemother Pharmacol; 2013 Nov; 72(5):1103-10. PubMed ID: 24057043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective, open, multi-centre phase I/II trial to assess safety and efficacy of neoadjuvant radiochemotherapy with docetaxel and oxaliplatin in patients with adenocarcinoma of the oesophagogastric junction.
    Moehler M; Gockel I; Roessler HP; Arnold D; Trarbach T; Thomaidis T; Klautke G; Rödel C; Brenner B; Lang H; Galle PR; Schimanski CC; Schmidberger H
    BMC Cancer; 2013 Feb; 13():75. PubMed ID: 23394629
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose-finding study of docetaxel, oxaliplatin, and S-1 for patients with advanced gastric cancer.
    Zang DY; Yang DH; Kim MJ; Jang KM; Hwang SW; Yoo KS; Han T; Kim HY; Kim HJ; Kwon JH; Song HH; Park S; Jung JY; Kim HS; Kim JH
    Cancer Chemother Pharmacol; 2009 Oct; 64(5):877-83. PubMed ID: 19190908
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I study of AMD473 and docetaxel given once every 3 weeks in patients with advanced refractory cancer: a National Cancer Institute of Canada-Clinical Trials Group trial, IND 131.
    Gelmon KA; Stewart D; Chi KN; Chia S; Cripps C; Huan S; Janke S; Ayers D; Fry D; Shabbits JA; Walsh W; McIntosh L; Seymour LK
    Ann Oncol; 2004 Jul; 15(7):1115-22. PubMed ID: 15205207
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I trial of docetaxel, oxaliplatin, and capecitabine (DOC) in untreated gastric cancer patients.
    Frustaci S; Buonadonna A; Turchet E; Corona G; Tabaro G; Miolo G; Torrisi E; Lo Re G; Tumolo S; Toffoli G
    Int J Clin Oncol; 2013 Jun; 18(3):510-6. PubMed ID: 22669361
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I study of pulsatile 3-day administration of afatinib (BIBW 2992) in combination with docetaxel in advanced solid tumors.
    Awada AH; Dumez H; Hendlisz A; Wolter P; Besse-Hammer T; Uttenreuther-Fischer M; Stopfer P; Fleischer F; Piccart M; Schöffski P
    Invest New Drugs; 2013 Jun; 31(3):734-41. PubMed ID: 23161334
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I and pharmacokinetic study of oxaliplatin and bortezomib: activity, but dose-limiting neurotoxicity.
    Kobrinsky B; Joseph SO; Muggia F; Liebes L; Beric A; Malankar A; Ivy P; Hochster H
    Cancer Chemother Pharmacol; 2013 Nov; 72(5):1073-8. PubMed ID: 24048674
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I and pharmacokinetic study of the multitargeted antifolate pemetrexed in combination with oxaliplatin in patients with advanced solid tumors.
    Misset JL; Gamelin E; Campone M; Delaloge S; Latz JE; Bozec L; Fumoleau P
    Ann Oncol; 2004 Jul; 15(7):1123-9. PubMed ID: 15205208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose escalation study on oxaliplatin and capecitabine (Xeloda) in patients with advanced solid tumors.
    Kakolyris S; Souglakos J; Kouroussis C; Androulakis N; Samonis G; Vardakis N; Amarantidis K; Agelaki S; Mavroudis D; Xenidis N; Georgoulias V
    Oncology; 2004; 66(4):253-9. PubMed ID: 15218291
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I trial of bortezomib in combination with docetaxel in patients with advanced solid tumors.
    Messersmith WA; Baker SD; Lassiter L; Sullivan RA; Dinh K; Almuete VI; Wright JJ; Donehower RC; Carducci MA; Armstrong DK
    Clin Cancer Res; 2006 Feb; 12(4):1270-5. PubMed ID: 16489083
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intermittent weekly high-dose capecitabine in combination with oxaliplatin: a phase I/II study in first-line treatment of patients with advanced colorectal cancer.
    Scheithauer W; Kornek GV; Raderer M; Schüll B; Schmid K; Längle F; Huber H
    Ann Oncol; 2002 Oct; 13(10):1583-9. PubMed ID: 12377646
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.